ACIU
What one share of Ac Immune Sa holds
Pharmaceutical Preparations
AC Immune is a leading, clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. Our highly differentiated approach aims to overcome the fundamental challenge in this therapeutic area – the high number of co-pathologies driving disease development and progression and the urgent need for more tailored therapeutic regimens.
Ac Immune Sa’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Sales | $0.04 |
|---|---|
| Profit | −$0.84 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.84 |
| Cash and investments | $0.33 |
| Book value | $0.56 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.47 | −$0.14 | $0.02 | −$0.13 | — | $2.80 |
| 2017 | $0.36 | −$0.47 | $0.03 | −$0.43 | — | $2.09 |
| 2018 | $0.11 | −$0.84 | $0.03 | −$0.76 | — | $2.67 |
| 2019 | $1.56 | $0.64 | $0.03 | $0.75 | — | $3.92 |
| 2020 | $0.23 | −$0.92 | $0.03 | −$0.91 | — | $3.39 |
| 2021 | $0.00 | −$1.07 | $0.04 | −$1.00 | — | $3.04 |
| 2022 | $0.05 | −$0.89 | $0.02 | −$0.94 | — | $2.19 |
| 2023 | $0.19 | −$0.71 | $0.01 | −$0.80 | — | $1.93 |
| 2024 | $0.31 | −$0.58 | $0.01 | $0.74 | — | $1.23 |
| 2025 | $0.04 | −$0.84 | $0.01 | −$0.84 | — | $0.56 |